affected [1] . Many etiological factors were suggested as candidates responsible for individual development of Dupuytren's disease, e.g. alcoholism [2] , smoking [3] , diabetes mellitus [4] , trauma [5] and genetic predisposition [6] . The diseased aponeurotic tissue possesses biological features of benign neoplastic fibromatosis and was recently characterized as a useful model of fibrosis because it displays the entire temporal and histological architecture of cells, cytokines and extracellular matrix involved in fibroproliferative processes [7] . Until now, only surgical therapy, namely partial and total aponeurectomy, is established in patients suffering from palmar fibrosis, however, recurrence rates in individuals undergoing surgery are still high [8, 9] . Thus, new therapeutic approaches are required for more effective treatment.
Similar to other fibroproliferative disorders, TGF-β is a pivotal factor during pathogenesis of palmar fibrosis by initiating a specific signalling pathway mediated by Smad proteins [10] . Given the critical role of TGF-β in fibrogenesis, promising new therapeutic strategies exist that target its profibrogenic signalling route in order to decrease cytokine dependent overexpression of extracellular matrix (ECM) proteins in Dupuytren's disease. Recently, N-acetyl-L-cysteine (NAC) was identified as a ubiquitously available drug capable of blocking TGF-β-dependent Smad pathway signalling in hepatic stellate cells and rat fibroblasts [11, 12] , thereby attenuating profibrotic capabilities of the cells.
This study addressed the question whether application of NAC can downregulate TGF-β dependent gene responses and protein expression in fibroblasts isolated from Dupuytren's disease.
Materials and methods

Materials
All reagents for cell culture (Dulbecco's modified Eagle medium (DMEM), fetal calf serum (FCS), Trypsin-EDTA and phosphate-buffered saline (PBS)) were from Gibco-BRL (Life Technologies, Rockville, USA) or BIOCHROM (Berlin, Germany). The monoclonal anti β-actin antibody was from Sigma (Munich, Germany). Polyclonal antibodies against PAI-1 and Col1A1 were from Santa Cruz Biotechnologies Inc., CA, USA. The monoclonal α-SMA antibody was from DAKO, Hamburg, Germany. The luciferase assay system was from Promega (Mannheim, Germany). All other chemicals were obtained from commercial sources at the purest grade available.
Cell culture
Tissues from Dupuytren's disease were obtained either by partial or total aponeurectomies of affected palmar fascias of 12 male (61 y ± 8.9) and 5 female (67 ± 9.3) northern European patients. All individuals suffered from contractures of the fingers rated as third degree deformities according to the Tubiana score [13] . Obtained tissues were separated by macroscopic appearance into cord and nodule origin and cultured separately. Normal tendon pulley fibroblasts were obtained from patients undergoing incision of tendon pulleys to treat tendovaginitis stenosans and served as controls. Written informed consent to the research use of material was obtained from all patients. The research protocol applied during the experiments was approved by the Ethics Committee of the Medical Faculty of the University of Erlangen.
Fibroblasts, either derived from cords of Dupuytren's disease (DF) or control tissues (CF), were isolated by using the explant culture technique as described [14] and grown in DMEM (Glucose 1.0 g/l, NaHCO 3 3.7 g/l, NAcetyl-L-alanyl-L-glutamine 1.0289 g/l, BIOCHROM) supplemented with 10% FCS, 40 µg/ml Gentamycin (GIBCO/BRL) without additional growth factors in 75 cm 2 culture flasks. All cultures were maintained at 37°C, 5% CO 2 in a humidified atmosphere. When cultures reached 70-80 % confluence, cells were subcultured or cryopreserved using 10% DMSO. For adenoviral infection, fibroblasts were seeded in 58 cm 2 Petri culture dishes (Greiner, Frickenhausen, Germany).
Vectors and gene transfer
Adenoviral stocks for (CAGA) 9 -MLP-Luc were created using the Adeasy cloning and recombination procedure (Quantum, Appligene, www.quantum-appligene.com). Infections and coinfections of fibroblasts isolated from Dupuytren's disease and healthy tendon pulleys were performed according to other reports [15] . Routine infections were accomplished with 2 x 10 5 Dupuytren fibroblasts (DF) or control fibroblasts (CF) following second subculture at 50 m.o.i. with single virus clones of the same virus stock preparation. Infection efficiency was proven by adenoviral constructs expressing β-galactosidase and, each time, about 90% of the cells were infected. Staining of infected cells was performed using an X-Gal staining kit (Roche, Mannheim, Germany). To perform luciferase assays, cells were cultured for 2 days in DMEM with 10 % FCS, and then infected with adenoviruses as indicated. Lysates for luciferase detection were prepared 24 hours after adenoviral infections. Adenoviral stocks for constitutively active TGF-β receptor I (AdcaTβRI) and Smad7 (AdSmad7) were described previously [16] and kindly provided by A. Moustakas, Ludwig Institute for Cancer Resarch, Uppsala, Sweden.
In vitro application of NAC and TGF-β 1
Following second subculture, CF and DF were adenovirally infected with Ad-(CAGA) 9 -MLP-Luc [17] . Infected fibroblasts were treated with 5 or 10 mM NAC and 5 ng/ml TGF-β 1 (R&D Systems, Wiesbaden, Germany) separately or in combination as indicated. Untreated cells served as controls. Luciferase activity was determined 6h following NAC exposition and determined as light cycles per second and well (LCPS/well).
Preparation of total cell lysates, nuclear extracts and Western blot analysis
Total lysates from CF and DF, treated with 5 mM or 10 mM NAC and untreated were prepared with 0.9 ml RIPA buffer [1U Tris buffered saline (TBS), 1% Nonidet P-40 (Amresco, Solon, USA), 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS)]; protease inhibitors were provided as Protease Inhibitor Mix (Roche) just before use according to manufacturer's instructions. To inhibit protein dephosphorylation, Phosphatase Inhibitor Mix (Sigma) was added. Using a syringe fitted with a 21 gauge needle to shear DNA, lysates were transferred to a microcentrifuge tube. 10 µl of a 10 mg/ml PMSF stock was added, followed by a 30 to 60 min incubation on ice. Subsequently, cell lysates were cleared by centrifugation at 15.000 x g for 20 min at 4°C. 40 µl of lysates were separated by SDS-8% polyacrylamide gel electrophoresis (PAGE) and transferred to a 0.45 µm nitrocellulose membrane (Protran BA 85; Schleicher&Schüll, Dassel, Germany) for Western blot analysis to determine expression of PAI-1, COL1A1 and α-SMA as previously described [18] . Individual band intensities were analyzed using Scion Image for Windows (Release Beta 4.0.2, Scion Corporation, Frederick, MA, USA) and calculated in relation to obtained β-actin blots.
Statistical analysis
For statistical analysis of results obtained from Ad-(CAGA) 9 -MLP-Luc experiments, GraphPad Prism (GraphPad Software for Science Inc., San Diego, California, USA) version 3.02 was used by applying the two tailed unpaired Student t test with a P value for significance set at least at 0.05.
Results
Reporter gene-infected DF and CF cells demonstrate functional Smad activity that can be inhibited by ectopic expression of Smad7
To evaluate intrinsic TGF-β downstream signal transduction, DF and CF were infected with an adenovirus containing a strongly responsive (CAGA) 9 -MLP-luc sequence, including 9 copies of a PAI-1 specific TGF-β response element [17] . Infection rates were about 90%, as examined by microscopical galactosidase activity after AdLacZ infection (Fig. 1A) . Both cell populations showed intrinsic stimulation of reporter gene activity with total counts of luciferase activity being higher in DF compared to CF in all experiments, indicating enhanced autocrine stimulation (Fig. 1B) . Overexpression of a constitutively active TGF-β type I receptor (AdcaTβRI) resulted in a 38-fold increase of reporter activity in CF [(7.767 ± 2.003), n = 12 vs. 
TGFβ 1 dependent activation of (CAGA) 9 -MLP-luc is downregulated by NAC
To evaluate the impact of NAC on TGF-β downstream signal transduction, CF and DF were infected with Ad(CAGA) 9 -MLP-luc and exposed to 5 and 10 mM NAC (Fig. 2A) . Both doses significantly reduced autocrine-stimulated luciferase activity in CF and DF, proving 10mM NAC more effective than 5 mM [CF vs. CF + 5 mM NAC: (233.667 ± 12.472), n = 12 vs. (136.333 ± 18.856) 160 Fig. 1 (B) (CAGA) 9 -MLP-luc dependent luciferase activity was measured 2 days after infection. The presented data are based on at least three independent experiments. LCPS, luciferase counts per second from collected data were measured ± SD and are indicated on top of each bar. Statistically significant differences (p < 0.05; Students t-Test) between CF and DF are indicated by #, and between various treatments within each cell type by *. To further substantiate the suppressive effect of NAC, cells were additionally stimulated with 5 ng/ml TGF-β 1 1h following exposition to 5 and 10 mM NAC and reporter activity was evaluated 3h later ( 
Application of NAC downregulates protein expression in CF and DF
Cell lysates of CF and DF were screened for expression of α-SMA, Col1A1 and PAI-1 as major indicators for impaired fibrotic matrix turnover under standard culture conditions and following exposure to NAC (Fig. 3) . 
Discussion
On the molecular level, there is evidence that Dupuytren's disease is influenced by a variety of growth factors [19, 20] . However, the transforming growth factor beta isoforms TGF-β 1 and TGF-β 2 have been demonstrated to be the most potent biochemical effectors during fibrogenesis of the palmar fascia [21] . Since TGF-β 2 has a strong effect on cell proliferation, TGF-β 1 causes cytokine depending expression of α-SMA that has been identified as a critical hallmark in many fibroproliferative disorders. Also in Dupuytren's disease, it represents the differentiation of fibroblasts to myofibroblasts, a crucial step during pathogenesis [22] [23] [24] . Further, fibromatosis of the palmar fascia is characterized by excessive accumulation of collagen organized as cords and nodules [25, 26] . In Dupuytren's disease, expression of both proteins is a prerequisite for contractile phenomena to occur on fingers as well as on the palma manus [22] . Whereas in healthy connective tissues protein turnover is balanced through a fine equilibrium of matrix deposition and degradation processes, fibrotic tissues show high levels of PAI-1 expression, thereby blocking catabolic processes in involved tissues and organs [27] . Like in Dupuytren's disease, TGF-β 1 has already been identified as crucial factor in other fibroproliferative diseases, e.g. in liver [8, 9, 15, 28, 29] , lung [30, 31] and kidney fibrosis [32] as well as in hypertrophic scar formation [33, 34] .
Our experiments demonstrate that fibroblasts isolated from Dupuytren's disease exhibit elevated endogenous levels of TGF-β 1 , a phenomenon, we have already described in hypertrophic scar derived fibroblasts [33] . Considering these findings, we have to postulate that progression of fibroproliferative processes in inflicted palmar fascias might be based on a self-perpetuating mechanism.
TGF-β 1 signalling is initiated by binding of the cytokine to type I and II receptors [35] . The activated type I receptor phosphorylates a subset of Smads, known as receptor-regulated Smads (RSmads), which associate with Smad4 and move into the nucleus [36, 37] . In the nucleus, this complex may associate with specific DNA-binding proteins that direct it to the regulatory region of target genes encoding for proteins like procollagen, α-SMA, fibronectin or PAI-1 [17] . Smad mediated signalling itself is regulating the expression of specific inhibitory Smads (I-Smads) capable of blocking the phosphorylation of Smad 2/3, thereby providing a regulatory system in healthy tissues. TGF-β 1 signalling is blocked by Smad7, whereas Smad6 is specific for bone morphogenetic protein signalling.
In hypertrophic scar derived fibroblasts, we have already demonstrated that ectopic overexpression of Smad7 abrogates the TGF-β signalling, thereby providing a therapeutic option for the treatment of fibrotic disorders [33] . However, since long term effects of in vivo overexpression or application of Smad7 remains unclear, other options have to be identified in order to establish new clinical strategies.
Recently, Meurer et al. identified NAC as a dosedependent antagonist of TGF-β signalling as measured by reporter gene activation, Smad2 and Smad3 phosphorylation, and regulation of Smad7 mRNA expression [11] .
Our results show that the application of NAC has comparable blunting effects on TGF-β signalling as ectopically overexpressing the natural antagonist Smad7. Related to the applied concentration, (CAGA) 9 -MLP-luc reporter activity was downregulated, thus indicating abrogation of cytokine specific signalling in a dose-dependent manner. Importantly, in-parallel expression of proteins relevant for matrix accumulation and tissue contraction is reduced below basal levels.
Details of how NAC provides anti-TGF-β action are still speculative. Meurer et al. have suggested that these effects are based on disintegration of TGF-β and TGF-β receptor endoglin complex formation, as well as a reduced ligand binding capacity to betaglycan [11] .
On the other hand, NAC is an efficient antioxidant and decreases oxidative stress, which was previously determined as a favouring multiplier of profibrogenic TGF-β effects [38] [39] [40] .
Since we applied NAC only for the short incubation period of 6h, its therapeutic use in Dupuytren's contracture would require longer administration. The effects of long-term administration of NAC will require further investigation, as its antioxidant properties might delay senescence or apoptosis in resident cells and might be influenced by the age of the recipient [41, 42] .
Details regarding anti-TGF-β and the antifibrotic function of NAC need to be established by further research. Since NAC is a ubiquitously available drug with no considerable side effects during short application periods, we consider its use a possible option in future clinical approach, especially in patients suffering from relapses of Dupuytren's disease.
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